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Abstract
Background: Glioblastoma (GBM) is a highly aggressive malignant primary brain tumor, characterized by rapid
growth, diffuse infiltration of cells into both adjacent and remote brain regions, and a generalized resistance to
currently available treatment modalities. Recent reports in the literature suggest that Signal Transducers and
Activators of Transcription (STATs) play important roles in the regulation of GBM pathophysiology.
Methods: STAT6 protein expression was analyzed by Western blotting in GBM cell lines and by
immunohistochemistry in a tissue microarray (TMA) of glioma patient tissues. We utilized shRNA against STAT6 to
investigate the effects of prolonged STAT6 depletion on the growth and invasion of two STAT6-positive GBM cell
lines. Cell proliferation was assessed by measuring
3H-Thymidine uptake over time. Invasion was measured using
an in vitro transwell assay in which cells invade through a type IV collagen matrix toward a chemoattractant (Fetal
Bovine Serum). Cells were then stained and counted. Kaplan-Meyer survival curves were generated to show the
correlation between STAT6 gene expression and patient survival in 343 glioma patients and in a subset of patients
with only GBM. Gene expression microarray and clinical data were acquired from the Rembrandt [1] public data
depository (https://caintegrator.nci.nih.gov/rembrandt/). Lastly, a genome-wide expression microarray analysis was
performed to compare gene expression in wild-type GBM cells to expression in stable STAT6 knockdown clones.
Results: STAT6 was expressed in 2 GBM cell lines, U-1242MG and U-87MG, and in normal astrocytes (NHA) but not
in the U-251MG GBM cell line. In our TMA study, STAT6 immunostaining was visible in the majority of astrocytomas
of all grades (I-IV) but not in normal brain tissue. In positive cells, STAT6 was localized exclusively in the nuclei over
95% of the time.
STAT6-deficient GBM cells showed a reduction in
3H-Thymidine uptake compared to the wild-type. There was
some variation among the different shRNA- silenced clones, but all had a reduction in
3H-Thymidine uptake
ranging from 35%- 70% in U-1242MG and 40- 50% in U-87MG cells. Additionally, STAT6- depleted cells were less
invasive than controls in our in vitro transmembrane invasion assay. Invasiveness was decreased by 25-40% and 30-
75% in U-1242MG and U-87MG cells, respectively. The microarray analysis identified matrix metalloproteinase 1
(MMP-1) and urokinase Plasminogen activator (uPA) as potential STA6 target genes involved in the promotion of
GBM cell invasion. In a Kaplan-Meier survival curve based on Rembrandt [1] gene expression microarray and clinical
data, there was a significant difference in survival (P < 0.05) between glioma patients with up- and down-regulated
STAT6. Decreased STAT6 expression correlated with longer survival times. In two subsets of patients with either
grade IV tumors (GBM) or Grade II/III astrocytomas, there was a similar trend that however did not reach statistical
significance.
Conclusions: Taken together, these findings suggest a role for STAT6 in enhancing cell proliferation and invasion
in GBM, which may explain why up-regulation of STAT6 correlates with shorter survival times in glioma patients.
This report thus identifies STAT6 as a new and potentially promising therapeutic target.
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Each year, roughly 18,000 new cases of malignant pri-
mary brain tumors are diagnosed in the United States,
the majority of which are gliomas. Of these, 50-60% are
classified as World Health Organization grade IV astro-
cytomas, or Glioblastomas (GBM) [2], which makes
GBM the most common primary brain tumor in adults.
GBM is also the most aggressive and most lethal type of
brain tumor, with an average patient life expectancy of
only 15 months after diagnosis [3]. GBM cells are not
only highly proliferative but also readily invade sur-
rounding brain structures, thereby making complete sur-
gical resection practically impossible [4]. Furthermore,
the majority of GBMs are intrinsically resistant to most
forms of radio- and chemotherapy [5,6], thus rendering
the standard arsenal of anti-cancer treatments rather
ineffective. The relatively recent addition of temozolo-
mide to standard treatment regimens consisting of sur-
gical resection and radiation extended median survival
time from 12.1 to 14.6 months and more than doubled
overall 2-year survival from 10.4 percent to 26.5 percent
[7]. While these therapeutic advances are encouraging,
there is clearly still a dire need for more effective thera-
peutic approaches. A better understanding of the
mechanisms controlling the GBM phenotype is essential
for the identification of new molecular targets.
The Signal Transducers and Activators of Transcrip-
tion (STAT) family of transcription factors consists of
seven members (STATs 1-4, 5a, 5b, and 6), several of
which possess properties of oncogenes. STAT3 for
instance, is up-regulated and active in breast, prostate,
lung, head and neck, pancreatic and colon cancer as
well as melanoma, leukemia and lymphoma [8-15].
Recently, STAT3 was reported to be over expressed and
active in gliomas, and its deletion induces spontaneous
apoptosis in glioma cell lines [16-18]. STAT5b appears
to play an important role in several aspects of GBM
pathophysiology, as was shown by Liang et al.w h o
demonstrated its involvement in glioma cell prolifera-
tion, cell cycle progression, and invasion [19].
Despite the fact that each STAT family member
responds to distinct stimuli, resulting in a specific cellu-
lar response, all STATs share a similar mechanism of
activation and function [9]. STAT activity is initiated by
phosphorylation of a conserved tyrosine residue near
the C terminus, most commonly by Janus Kinases
(JAKs). Receptor tyrosine kinases such as the epidermal
growth factor receptor (EGFR) and platelet-derived
growth factor receptor (PDGFR), as well as non-receptor
tyrosine kinases (i.e. v-Src, v-Abl) can also phosphory-
late STAT proteins [20,21].
Tyrosine phosphorylated STATs form dimers and
translocate to the nucleus, where they bind their target
DNA sequence, recruit co-activators and initiate
transcription of target genes. Over 100 potential STAT
target genes have been identified [21], many of which
are involved in the control of cell proliferation, differen-
tiation, and apoptosis [22]. Altered expression of these
genes has been linked to cellular transformation and
oncogenesis [9]. Specifically, STATs 3 and 5b induce
members of the Bcl-2 family of anti-apoptotic regulatory
proteins [23,19] as well as cyclin D1, which promotes
cell-cycle progression [24,25]. Additionally, STAT3 regu-
lates the expression of the c-Myc transcription factor,
which facilitates cell proliferation and survival and is fre-
quently over-expressed in human cancers [24,26,27].
In non-transformed cells, STAT signaling is transient
and results from the activation of specific pathways.
Constitutive activation of STATs has, however, been
demonstrated in several human malignancies including
breast, lung, prostate, pancreatic and renal cancer, as
well as several types of leukemia and lymphoma [9].
The activation of STATs in transformed cells is gener-
ally achieved by over-activity of tyrosine kinases, either
due to an activating mutation in the kinase itself, or as a
result of increased signaling by cytokines and growth
factors. In breast cancer, for instance, increased STAT
activity is a consequence of excessive signaling of the
EGFR pathway and c-src [9]. These aberrantly activated
STATs can render the cell independent of cytokine- or
growth factor-induced signals, while simultaneously
altering the normal gene expression pattern in favor of
growth and survival.
Compared with other STAT family members, the
involvement of STAT6 in human cancer has received
limited attention. Nevertheless, STAT6 is over-expressed
and active in numerous malignancies including prostate
and colon cancer [28,29], lymphoma [30-32], and leuke-
mia [33,34]. Furthermore, STAT6 has been implicated
in the prevention of apoptosis in human colon cancer
cells [35], and its expression in these cells positively cor-
relates with increased invasive and metastatic capabil-
ities [29].
In this study, we investigated the involvement of
STAT6 in GBM proliferation and invasion. First, we
showed robust STAT6 expression in 2 of 3 GBM cell
lines. In a tissue microarray (TMA) of human glioma
patients, glioma tissue specimens consistently exhibited
higher STAT6 levels than did non-malignant brain tis-
sue. Expression levels however did not appear to corre-
late with tumor grade. We further demonstrated that in
at least one GBM cell line, STAT6 exhibited basal activ-
ity in the absence of external stimuli- an observation
that agrees with the predominantly nuclear localization
seen in immunohistochemistry of human glioma tissues.
Additionally, STAT6 was activated by relevant signalling
molecules in vitro, including epidermal growth factor
(EGF), whose receptor is frequently up-regulated/
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times in patients. Kaplan-Meier survival curves gener-
ated with Rembrandt [1] -derived patient data also
showed a correlation between higher STAT6 expression
and decreased survival of glioma patients. Finally, GBM
cells in which STAT6 had been silenced with shRNA
exhibited markedly decreased rates of proliferation and
invasion compared with wild-type GBM cells. A gene
expression microarray identified MMP-1 and uPA as
potential STAT6 target genes and downstream modula-
tors of cell invasion.
Methods
Reagents
EGF was purchased from Chemicon/Millipore (Billerica,
M A ) .T h et i s s u em i c r oa r r a y( T M A ) ,t h ea n t i b o d y
against STAT6 used for Immunohistochemistry (Ab641)
and the phospho-STAT6 (Tyr641) antibody were pur-
chased from Imgenex Corp. (San Diego, CA). Rabbit
polyclonal antibodies against STAT5a and STAT6 used
for Western blotting were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). Rabbit polyclonal
antibodies against STAT1, STAT2, STAT3 and STAT4
were purchased from Cell Signaling Technology (Bev-
e r l y ,M A ) .T h ea n t i b o d ya g a i n s tS T A T 5 bw a sag e n e r -
ous gift from Dr. C. Silva (University of Virginia). The
mouse monoclonal a-tubulin antibody (Product Num-
ber T6074), MISSION shRNA Lentiviral Transduction
Particles against STAT6 (Product Number NM_003153)
and MISSION Non-Target shRNA Control Transduc-
tion Particles (Product Number SHC002V) were pur-
chased from Sigma-Aldrich (St. Louis, MO). The HG-
U133_Plus_2 gene chip was purchased from Affymetrix
(Santa Clara, CA).
Cell Culture
The U-1242MG and U-251MG cell lines were gener-
ously supplied by Dr. A.J. Yates (Ohio State University)
and Dr. DD Bigner (Duke University), respectively. Both
cell lines were isolated from characterized GBM tumors
and have been extensively described elsewhere [36]. The
U-87MG cell line was obtained from American Type
Culture Collection (Manassas, VA). Cells were cultured
in minimal essential medium-a (MEM- a) supplemen-
ted with 10% fetal bovine serum (FBS) (Hyclone, Logan,
Utah) and 1% penicillin/streptomycin (Invitrogen) at 37°
Ci n4 . 8 %C O 2, 90% relative humidity unless stated
otherwise.
Primary cultures of human fetal astrocytes (NHA)
were obtained from Clonetics (San Diego, California)
and cultured in a growth medium containing 25 μg/ml
bovine insulin, 20 ng/ml EGF, 5% fetal bovine serum, 20
ng/ml progesterone, and 50 μg/ml transferrin at 37°C in
4.8% CO2, 90% relative humidity.
Western blot analysis
Cells were rinsed with 1x phosphate buffered saline
(PBS; 137 mM NaCl, 8.1 mM Na2HPO4,2 . 7m MK C l ,
and 1.5 mM KH2PO4, pH 7.4) containing 0.2 mM
sodium orthovanadate and protein was extracted using
Triton lysis buffer [1% Triton X-100, 50 mM Tris, pH
7.5, 150 mM NaCl, 2 mM EDTA, and Protease Inhibitor
Cocktail (Sigma-Aldrich, Product Number P8340)] addi-
tionally containing 2 mg/ml sodium orthovanadate
(phosphorylation studies only) and 5 mg/mL DTT
unless otherwise noted. Western blot analysis was per-
formed as previously described [36].
RNA extraction
Cells were grown to 90% confluence in 100 mm plates
in MEM- a medium with 10% FBS and 1% penicillin/
streptomycin. Each dish was lysed at room temperature
by applying 1 ml of Trizol reagent (Invitrogen) and
gently pipetting up and down until all cells were sus-
pended in the solution. Lysates were combined with
200 μl of chloroform in RNAse/DNAse free 1.5 ml cen-
trifuge tubes and centrifuged at 14,000 × g for 15 min-
utes. Upon removal from the centrifuge, the mixture
consisted of two layers; the top layer containing the
RNA was carefully transferred into a new 1.5 ml centri-
fuge tube and combined with 500 μl of isopropanol at -
20°C overnight to facilitate RNA precipitation. The next
day, RNA was pelleted by centrifugation at 14,000 × g
for 10 minutes. The supernatant was removed, and the
RNA pellet was washed once by adding 1 ml of 75%
ethanol followed by centrifugation at 8,000 × g for 5
minutes. The ethanol was removed, and the pellet was
allowed to dry in the open tube for about 10-15 min-
utes depending on pellet size. The dry pellet was then
re-suspended in RNAse free/DEPC water (10-20 μl
depending on pellet size) and concentration was deter-
mined by spectrophotometer.
Real-time (quantitative) PCR
Primers were designed using Primer Express 2.0
(Applied Biosystems), based on target sequences
retrieved from the Affymetrix Probe Sequence Database
(Liu et al., 2002). Total RNA samples were prepared as
described above. Reverse transcription PCR was per-
formed using MultiScribe reverse transcriptase (Applied
Biosystems, Forster City, CA) and random hexamers as
per the manufacturer’s instruction, to generate cDNAs.
Real time quantitative PCR using SYBR Green I was
then performed on the cDNAs in an Applied Biosystems
7900 Sequence Detection System. Samples were run in
triplicate. In order to verify that only a single PCR pro-
duct was amplified per transcript, dissociation curve
data was analyzed through the 7900HT Sequence Detec-
tion Software (SDS). To account for differences in
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for each cDNA sample using housekeeping genes
synthesized at our own facility, hypoxanthine-guanine
phosphoribosyltransferase (HPRT) and b-actin. The data
collected from these quantitative PCRs defined a thresh-
old cycle (Ct) of detection for the target or the house-
keeping genes in each cDNA sample. Analysis of the
variance (ANOVA) was then performed to determine
the mean and standard error for each comparison.
shRNA gene silencing
U-1242 MG and U-87MG cells were seeded in 6-well
plates and grown to 60% confluence in MEM- a med-
ium with 10% FBS, at 37°C in 4.8% CO2,9 0 %r e l a t i v e
humidity Six wells of each cell line were then trans-
duced with one of five MISSION lentiviral shRNA
transduction particles targeting STAT6 or with a control
(non-targeting) shRNA, according to manufacturer pro-
tocol (Titer: 10^6 TU). The vector for all shRNAs was
pLKO.1; the five STAT-6 targeting sequences were as
follows:
TRCN0000019409: CCGGGCAGGAACATACAGA
CACATTCTCGAGAATGTG TCTGTATGTTCCTG
CTTTTT
TRCN0000019410: CCGGGCCTTCTTATGACCTT
GGAATCTCGAGATTCCAA GGTCATAAGAAGG
CTTTTT
TRCN0000019411: CCGGGCTTGATAGAAACTCC
TGCTACTCGAGTAGCAG GAGTTTCTATCAAG
CTTTTT
TRCN0000019412: CCGGGCCACTTTCAGACAA
ATACTTCTCGAGAAGTATT TGTCTGAAAGT
GGCTTTTT
TRCN0000019413: CCGGGTCGCAGTTCAACA
AGGAGATCTCGAGATCTCCT TGTTGAACTGC
GACTTTTT
48 hours after transduction, 1.5 μg/ml puromycin
was added to each well. Cells were selected for resis-
tance for 10 days, after which the mixed culture was
screened for STAT6 expression by Western blot analy-
sis. Each sample was also screened for off-target effects
on STATs 3, 5a and 5b at this time. These three
STATs were chosen due to their documented impor-
tance in GBM in the literature [16-19,39,40]. Mixed
cultures displaying the best knockdown of STAT6 in
combination with the fewest off-target effects were
subsequently subjected to dilution cloning: cells from
the mixed cultures were plated at a density of one cell
per well of a 96-well plate, and each clone was
expanded and screened for STAT6 expression by Wes-
tern blot analysis. For U-87MG, TRCN0000019409 and
TRCN0000019413 were the two sequences with the
best results; for U-1242MG it was TRCN0000019411
and TRCN0000019413. Clones derived from each
sequence were named accordingly; for example,
U-1242MG clone 11:22 was originally transduced
with sequence TRCN0000019411, while U-87MG
clone 13:38 was transduced with sequence
TRCN0000019413.
3H-Thymidine Incorporation
The relative rate of cell proliferation was determined by
the measurement of
3H-thymidine incorporation into
DNA, as previously described [36]. Briefly, cells were
counted and plated in 24-well plates at a density of
1.5×10
4 cells/well (U-1242MG) or 5×10
5 cell/well (U-
87MG). Cells were allowed to grow for 72 h in MEM- a
medium supplemented with 10% FBS and 1% penicillin/
streptomycin (Invitrogen) at 37°C in 4.8% CO2, 90%
relative humidity, then pulsed with
3H-thymidine (1
μCi/mL) for 4 h. Cells were washed 3× with 1 ml/well
cold 1x PBS, fixed with 1 ml/well of 10% trichloroacetic
acid (TCA) for 10 minutes on ice, washed 3x with
room-temperature PBS (1 ml/well), and permeabilized
in 1 ml/well 1N NaOH overnight at room temperature.
The pH was then neutralized with an equal volume (1
ml/well) of 1 M HCl and the solution was transferred
into scintillation vials containing Ready-Safe scintillation
fluid (10 mL). A Beckman Liquid Scintillation Counter
was used to quantify
3H-thymidine uptake by the cells.
All samples were run in triplicate, and each assay was
repeated three times.
In vitro Invasion Assay
Invasion was determined using a variation of the Boyden
chamber assay, as described in [37]. Briefly, cells were
trypsinized and counted; next, 5 × 10
5 cells (U-87MG)
or 1.5 × 10
4 cells (U-1242MG) were suspended in 300
μl of either serum-free MEM-a (U-1242MG) or MEM-
a containing 0.1% FBS (U-87MG). The cells were
seeded into the upper compartment of a Type IV col-
lagen (Sigma) coated polycarbonate filter with a pore
size of 8.0 μm (Becton Dickinson) in a 24-well plate.
Each polycarbonate filter had been coated with 10 μlo f
30% Type IV collagen 24 h before the addition of cells.
500 μlM E M - a medium containing 10% FBS was added
to the lower compartment as a chemo attractant. After
8 h of incubation at 37°C in 4.8% CO2, 90% relative
humidity, filters were fixed and stained: the medium was
removed from the top and bottom chambers and
replaced with a 0.1% crystal violet stain for 1 minute at
room temperature. The filters were then gently rinsed
with de-ionized water to remove excess crystal violet.
Cells in the upper compartment were removed, leaving
only the cells on the underside of the filter- these repre-
sented those cells who had successfully invaded across
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under a LEICA DMIRE 2 microscope using a QImaging
RETIGA EXi digital camera. The entire visual fields
were photographed, and the cells were counted. All
samples were run in triplicate, and assays were repeated
at least twice.
Tissue Microarray and Immunohistochemical Staining
The Tissue Microarray was purchased from Imgenex
(San Diego, CA). It included tissue sections from 8
patients with WHO Grade IV astrocytoma (GBM), 5
patients with Grade III (anaplastic) astrocytoma, 17
patients with Grade II (diffuse) astrocytoma, 8 patients
with Grade I (pilocytic) astrocytoma. It also included 8
sections of normal brain tissue.
Slides were deparaffinized in xylene and rehydrated in
ethanol according to manufacturer protocol. Immunos-
taining was performed using a STAT6 primary antibody.
Two independent investigators visually classified each
tissue sample as either STAT6 positive or negative. It
should be noted that STAT6 was frequently and highly
expressed in vascular endothelial cells surrounding
blood vessels seen in the specimens; however a designa-
tion of positive or negative was used to refer exclusively
to STAT6 expression in tumor cells.
Statistical Analysis
The mean and standard error of the mean (S.E.M.) were
calculated for each triplicate point by using Prism VI
(Graphpad Software, San Diego, CA, USA), and error
bars represent the S.E.M.. Each experiment was per-
formed a minimum of three times. Numerical values of
each separate run were normalized against the Non-Tar-
get Control to generate the graphs (Figures 5 and 6).
Statistical significance was calculated via One-way
ANOVA followed by Dunnett’s Multiple Comparison
Test, in reference to the Non-Target Control rather
than the wild type. However, all samples labeled with an
* were also significantly different from the wild type in
the same analysis. The level of significance was taken at
P < 0.05 at a confidence interval of 95%.
Kaplan-Meier Survival Plot
Ethics Statement
All human subjects data was publicly available in de-
identified form on the Rembrandt website (https://cain-
tegrator.nci.nih.gov/rembrandt/). Therefore, its use was
not classified as human subjects research, and no Insti-
tutional Review Board approval was needed.
Patient Datasets and Data Analysis
Both the microarray gene expression data and the clini-
cal data were obtained from the NCI Repository for
Molecular Brain Neoplasia Data (REMBRANDT)
database (https://caintegrator.nci.nih.gov/rembrandt/)
[1], using data available on October 1
st, 2010. The clini-
cal data were originally obtained from contributing insti-
tutions including the Henry Ford Hospital, UCSF, Lee
Moffitt Cancer Center, Dana Farber Cancer Center, Uni-
versity of Wisconsin, and NCI. Diagnoses were also
made at the respective clinics. At the time of access, 343
glioma patient samples with both gene expression data
and corresponding survival t i m e sw e r ea v a i l a b l eo nt h e
Rembrandt database. These included 181 GBMs, 105
grade II/III astrocytomas, 50 grade II/III oligodendro-
gliomas and 7 mixed gliomas.
Three Kaplan-Meier survival curves were generated:
one using available data on all glioma patients (n =
343), another looking at GBM patients only (n = 181),
or only using data on Grade II/III astrocytoma patients
(n = 105). The graphs were created using Rembrandt
microarray data for the probes from the Affymetrix
U133 Plus 2.0 GeneChip and associated survival data.
The “Highest Geometric Mean Intensity” of STAT6 was
used as the reporter for relative STAT6 expression
within the database. STAT6 up- or down-regulation was
defined as a 2-fold (or greater) difference from the
mean expression level within a given data set. For exam-
ple, up-regulation among GBM patients refers to a 2-
fold (or greater) increase in STAT6 expression, com-
pared to the average STAT6 expression levels in all
patients within the GBM sub-population. Therefore,
each patient sub-population (GBM, astrocytoma, or all
gliomas) has a distinct baseline, and individual patients’
STAT6 expression levels are only compared to other
patients in the same sub-population.
Affymetrix microarray
Microarray analysis of Affymetrix chips was performed
as previously described in [38]. Briefly, total RNA was
extracted from wild type and STAT6-deficient U-
1242MG and U-87MG cells. Biotin-labeled cRNA was
prepared from approximately 2 ug of total RNA and
hybridized to Human Genome U133-plus 2 (HG-
U133_Plus_2) Affymetrix oligonucleotide arrays, which
contain approximately 56,400 transcripts of human
genes or ESTs. After washing in a fluidic station, the
arrays were scanned with a 2.5-micron resolution Affy-
metrix Microarray Scanner (Affymetrix, Santa Clara,
CA). Scanned images were first examined for visible
defects and then checked for fitness of the gritting. The
image file was then analyzed to generate a raw data file.
From this point on a coordination of two paths of analy-
sis was carried out using Affymetrix Microarray Analysis
Suite 5.0 (MAS 5.0, Affymetrix, Santa Clara, CA) and
Dchip software [39]. The detection of a particular gene,
called “present”, “absent”,o r“marginal”, was made using
the nonparametric Wilcoxon ranked score algorithm as
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imported into and utilized by the Dchip program. Scat-
ter plots were also generated using this software to
inspect the reproducibility of the replicates as well as
the degree of variations of the samples under compari-
son. Quantitation of the genes was performed using
Dchip, which applied a model-based approach to derive
the probe sensitivity index and expression index. The
two indices were used in a linear regression to quantify
a particular gene. When specific probes or transcripts
deviated from the model to a set extent, they were identi-
fied as outliers and thus excluded from the quantitation
process. Normalization of the arrays was performed using
the invariant set approach. Comparative analysis of the
samples using Dchip generated fold changes and paired
sample t-test p-values. We considered a p < = 0.05 and a
fold change > = 1.5 in combination of a % Present > = 50
as an indication of significant change in gene expression
for up-regulation or down-regulation. A Spearman corre-
lation coefficient was generated for all possible pairs
involved using the Dchip quantitation results for quality
control. Hierarchical clustering of the genes was per-
formed after an appropriate filtration of the data.
Results
STAT6 is expressed in GBM cell lines and patient
astrocytoma specimens
It has been reported by others [40,19] that STATs 3 and
5 are expressed in GBM, where they perform numerous
oncogenic functions. Specifically, high STAT3 expres-
sion contributes to cell cycle progression, survival, and
immune evasion in GBM [18,41-43], while STAT5 facili-
tates GBM cell proliferation and invasion [19]. Rahaman
et al. [44] showed that STAT6 is also expressed in GBM
cell lines.
In order to establish the expression profiles of STATs
in GBM, we examined protein expression levels of all
s e v e nS T A T sb yW e s t e r nb l o ta n a l y s i si nt h r e eG B M
cell lines (U-1242 MG, U-87 MG and U-251 MG) and
compared them to expression levels in non-malignant
fetal astrocytes ("normal human astrocytes”, NHAs) (Fig-
u r e1 A ) .N o ts u r p r i s i n g l y ,S T A T s3 ,5 aa n d5 bw e r e
each up-regulated in at least one GBM cell line com-
pared with NHAs, confirming earlier reports in the lit-
erature [19,42]. STAT6 protein expression was markedly
increased in two of the three GBM cell lines (U-1242
MG and U-87MG) when compared with the NHAs.
Alpha-tubulin was used as the loading control.
Next, we wanted to assess whether increased STAT6
protein levels in GBM cells were a direct consequence
of elevated mRNA levels, or if they were primarily a
result of slower protein turnover. We therefore exam-
ined STAT6 mRNA levels in each cell line by real-time
(quantitative) PCR. Figure 1b shows relative levels of
STAT6 mRNA in NHAs, U-1242MG, U-251MG and U-
87 MG cell lines, normalized to the housekeeping genes
hypoxanthine-guanine phosphoribosyltransferase
(HPRT) and b-actin. In U-1242MG cells, mRNA for
Figure 1 STAT6 Expression in GBM cells. Figure 1a: Western blot comparing expression of STATs 1-6 in NHA and three GBM cell lines. STATs
1, 3, 5a, 5b and 6 are over-expressed in at least one GBM cell line compared to the non-malignant astrocytes. STAT4 was not expressed in GBM
or NHA. Figure 1b: Real-time (quantitative) PCR showing increased STAT6 mRNA in 2 of 3 GBM cell lines compared to NHA. mRNA expression
was normalized by the geometric mean of the housekeeping genes beta actin and HPRT.
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NHAs, and was also much higher than in the other two
GBM cell lines (Figure 1B). U-87MG cells also had
increased STAT6 mRNA levels compared with the con-
trol; however, this was a more modest increase of only
about 50%. The mRNA expression pattern of STAT6 in
the four cell lines therefore generally agrees with
STAT6 protein expression levels, which also were
increased in U-1242MG and U-87MG, but not in U-
251MG cells when compared with NHAs. Nevertheless,
the 4-fold difference in STAT6 mRNA between U-
1242MG and U-87MG was not apparent at the protein
level.
Taken together, these results suggest that an increase
in mRNA levels likely contributes to the increased
expression of STAT6 seen at the protein level. Whether
the elevated transcript levels are due to increased tran-
scription or improved mRNA stabilization remains to be
determined. Additionally, it is possible that protein turn-
over of STAT6 in GBM cells is abnormal as well, which
would explain the high STAT6 protein levels in U-
87MG cells in the absence of a corresponding increase
in the transcript.
STAT6 is expressed in gliomas of Grades I-IV, but not in
normal cortex
In order to relate our in vitro findings to actual human
patient tumor specimens, we utilized a tissue microarray
(TMA) to evaluate STAT6 expression in GBM, healthy
brain, and lower grade gliomas by immunohistochemis-
try (IHC). Two independent investigators examined 8
sections each of normal cortex, Grade I (pilocytic) astro-
cytoma, and Grade IV astrocytoma (GBM), as well as 5
sections of Grade III (anaplastic) astrocytoma and 17
sections of Grade II (diffuse) astrocytoma, and evaluated
the extent and intensity of STAT6 staining in each sam-
ple. Figure 2 shows examples of images from the TMA,
and the numerical results of all TMA sections are sum-
marized in Table 1. Tumor-associated endothelial cells,
which frequently displayed high intensity staining of
STAT6, were disregarded when describing a sample as
STAT6 positive or negative.
No STAT6 staining was seen in the 8 sections of nor-
mal cortex. It is, however, likely that expression levels
were simply too low to be detectable by IHC in our
study, given previous reports of STAT6 expression in
astrocytes [44] and our own findings that STAT6 is
expressed, albeit at low levels, in NHAs.
STAT6 staining was observed in 5 of 8 (62.5%) pilocy-
tic astrocytomas (Grade I), 14 of 17 (82.3%) diffuse
astrocytomas (Grade II), 5 of 5 (100%) anaplastic astro-
cytomas (Grade III) and 4 of 5 (83.4%) GBM. There
does not appear to be a correlation between STAT6
expression and tumor grade, suggesting STAT6 may
play a role early in the process of transformation. The
fact that STAT6 over-expression is consistently main-
tained in high-grade astrocytomas does imply possible
additional functions for STAT6, potentially involving
tumor maintenance and/or progression.
EGF induces STAT6 tyrosine phosphorylation in vitro
It is generally accepted that STATs are phosphorylated
in response to growth factor signaling in a variety of
cancer cell lines [9]. The EGF receptor (EGFR) is fre-
quently amplified, over-expressed or mutated in GBM
where it plays a vital role in tumor development and
maintenance [5]. Increased EGFR expression and activ-
ity- both as a response to external stimuli or due to a
gain-of-function mutation- correlate with an exception-
ally poor prognosis in human GBM patients.
To determine whether EGFR signaling regulates
STAT6 activity in our GBM cells, we treated U-1242MG
and U-87MG cells with EGF (50 ng/mL) for 5 minutes,
lysed the cells and assessed STAT6 tyrosine phosphoryla-
tion (pY645) by Western blotting. In both cell lines, sti-
mulation with EGF resulted in robust tyrosine
phosphorylation of STAT6, indicating that STAT6 is in
fact activated by this signaling pathway (Figure 3). In
addition, basal phosphorylation of STAT6 was observed
in the U87MG cell line but not in U1242 cell line.
shRNA silencing of STAT6 in U-1242MG and U-87MG cells
We employed a lentiviral delivery system to stably
decrease expression of STAT6 in the U-1242MG and
U-87MG cells. Cells were transduced with one of five
unique shRNA sequences, and the resulting mixed cul-
tures were screened for successful STAT6 knockdown
by Western blot analysis. Each mixed culture was also
examined for expression of STAT3, STAT5a and
STAT5b (not shown) to avoid misleading results due to
non-specific knockdown of these other STATs. There is
ah i g hd e g r e eo fh o m o l o g yb e t w e e nm e m b e r so ft h e
STAT family, and significantn o n - s p e c i f i ck n o c k d o w n
was observed in at least one sequence for each cell line.
Those mixed cultures derived from sequences that
resulted in efficient STAT6 knockdown in the absence
of obvious off-target effects were chosen for dilution
cloning. Individual cells were expanded into clonal colo-
nies and again screened for stable STAT6 knockdown.
STAT6-deficient clones from each cell line were again
screened for non-specific knockdown of other STATs.
We chose to test for expression of STAT5b and STAT3
in U-87MG and U-1242MG, respectively, based on our
previous results when screening the mixed cultures. In
U-1242MG, for example, sequences 11 and 13 were the
most effective and specific; there was virtually no knock-
down of STAT5a or STAT5b, but a slight reduction in
STAT3 expression was observed. Therefore, when
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screen for STAT3 so that clones with normal STAT3
levels could be selected (Figure 4A). In U-87MG,
STAT5b was most likely to be affected based on the
mixed culture screens, possibly because STAT3 is
expressed at very low levels in this cell line. We
therefore chose to examine STAT5b expression as our
specificity control for the individual clones (Figure 4B).
Control cells were also created for each cell line by
infecting wild-type cells with a non-target shRNA in a len-
tiviral vector. As Figure 4 shows, these “non-target Con-
trol” groups had STAT6 levels similar to the wild-type
cells while the knockdown clones showed a significant
reduction in STAT6 protein expression. As seen in Figure
4A, there was a non-specific decrease in STAT3 in some
o ft h es t a b l eS T A T 6k n o c k d o w nc l o n e s .T h e s ec l o n e s
(labeled with *) were excluded from experiments. Given
that in earlier screening experiments, different STAT6
shRNA sequences resulted in off-target knockdown of dif-
ferent STATs, this is most likely a result of high sequence
homology between STATs and not a specific biological
consequence of reduced STAT6 expression.
shRNA-mediated gene silencing of STAT6 decreases
proliferation of U-1242MG and U-87MG cells
In order to investigate the physiological importance of
STAT6 in GBM, we measured
3H-thymidine incorporation
Figure 2 Tissue Microarray (TMA), representative images of staining categories. All images were probed for total STAT6 protein by IHC.
Upper left: tissue sample of a Grade III (anaplastic) astrocytoma showing high staining intensity in the nuclei of the majority of cells. Upper right:
GBM tissue sample demonstrating an example of low staining: some nuclei exhibit dark staining, but less than half the cells are positive for
STAT6. Lower left: GBM sample showing weak staining intensity in the majority of nuclei. This was also called low staining. Lower right: Tissue
sample of normal brain, showing no STAT6 staining in the nucleus or elsewhere.
Table 1 Comparison of STAT6 expression between
Grades I-IV astrocytomas and normal brain on the TMA
STAT6 Expression (%)
N Negative Positive
Normal Brain 8 8 (100%) 0
Pilocytic Astrocytoma
(Grade I)
8 3 (37.5%) 5 (62.5%)
Diffuse Astrocytoma
(Grade II)
17 3 (17.6%) 14 (82.4%)
Anaplastic Astrocytoma
(Grade III)
5 0 5 (100%)
Glioblastoma
(Grade IV)
6 1 (16.6%) 5 (83.4%)
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wild-type cells and in the STAT6-deficient clones. As pre-
sented in Figure 5, the STAT6 knockdown clones exhibited
significantly reduced
3H-thymidine uptake compared with
the wild-type in both U-1242MG and U-87MG cells. In
both cell lines,
3H-thymidine incorporation was reduced by
40% or more in all STAT6 knockdown clones, with some
of the U-1242MG clones exhibiting up to a 70% decrease
in uptake. As expected, the
3H-thymidine uptake of the
non-target control was not significantly different from the
wild-type in either cell line (Figure 5). These findings indi-
cate that depletion of STAT6 from U-1242MG and U-
87MG cells adversely affected their proliferative capacity,
which suggests that one role of STAT-6 over-expression in
GBM is to confer an enhanced growth rate and thereby, a
selective advantage to individual tumor cells.
STAT6 depletion by shRNA inhibits the invasion of glioma
cells in vitro
GBMs are highly invasive tumors that often recur in
remote brain areas less than a year following surgical
resection. This high recurrence rate is in large part
responsible for the dismal prognosis for GBM patients,
as it makes surgical removal of the primary tumor mass
an ineffective means of treatment. A better understand-
ing of the mechanisms underlying the invasive behavior
of GBM cells may provide clues on how to prevent or
delay tumor recurrence in human patients.
In order to determine whether STAT6 is involved in
mediating the invasiveness of GBM cells, we performed
an in vitro invasion assay on wild type GBM cell lines,
non-target control cells and the STAT6 knockdown
clones. Equal numbers of cells were allowed to invade
through a membrane coated with Type IV collagen sub-
strate, toward a chemo attractant (1% FBS) for 8 hours.
The invaded cells were fixed, stained and counted. We
purposely chose a relatively short time point (8 h), in
order to avoid a potential alteration of results by the dif-
fering cellular growth rates. The use of serum-free or
very low-serum medium for U-1242MG and U-87MG,
respectively, served as an additional control since neither
cell line actively proliferates in the absence of serum.
Figure 6 shows that the STAT6 knockdown cells were
considerably less invasive than the wild type or non-tar-
get control cells (Figure 6A and 6B). This was the case
for both cell lines, although the effect was more dra-
matic in U-87MG STAT6 knockdown clones, which
exhibited a decrease in invasion of up to 80%, compared
with wild type (Figure 6B). In U-1242MG, invasion was
decreased by 25-35% following STAT6 depletion, while
the non-target control cells invaded in similar numbers
to the wild-type in both cell lines. The shRNA-silencing
seemed to be more efficient in U-87 than in U1242,
which may explain the invasion results. Importantly,
there is no obvious correlation between individual
Figure 3 STAT6 activation by EGF. The GBM cell lines U-1242MG
and U-87MG were serum-starved for 12h followed by treatment
with EGF (50 ng/mL) for 10 min before lysis. Whole cell lysates were
probed for the tyrosine phosphorylated form of STAT6. EGF
treatment potently phosphorylated STAT6 on Y645 in both cell lines.
STAT6 was also basally phosphorylated at a lower level in the U-
87MG but not the U-1242MG cells.
Figure 4 STAT6 depletion by shRNA in two GBM cell lines. U-1242MG and U-87MG cells were transduced with lentivirus containing either
non-target shRNA or shRNA directed against STAT6, followed by selection with puromycin. Single-cell clones were screened for levels of STAT6.
Figure 4a: Five representative clones are shown for U-1242MG. Expression of STATs 3 and 5b was not affected by shRNA against STAT6. Tubulin
was the loading control. Figure 4b: Three representative clones are shown for U-87MG. Expression of STAT5b is not affected, and tubulin
demonstrates even loading.
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Page 9 of 16clones that were least invasive and those with the great-
est decrease in proliferation, suggesting that differences
in cellular growth rates were not responsible for the
results seen in the invasion assay.
Changes in gene expression following STAT6 knockdown
are cell-line dependent
While the apparent link between STAT6 expression and
several aspects of GBM malignancy is intriguing, STAT6
itself is a transcription factor and as such, exerts its cellular
effects by means of transcriptional targets. To our knowl-
edge, STAT6 gene targets in GBM have not been
described. We were therefore curious to see which genes
would be differentially expressed following STAT6 knock-
down in U-1242MG and U-87MG cells. In order to arrive
at a comprehensive list of potential STAT6 target genes,
we performed a microarray analysis on wild type U-
1242MG and U-87MG cells as well as three STAT6
knockdown clones from each cell line. We utilized Human
Genome U133-plus 2 Affymetrix oligonucleotide arrays,
which contain approximately 56,400 transcripts of human
genes or ESTs and thus provide a fairly complete overview
of changes in gene expression. For each cell line, we com-
pared the wild type to the group of the three clones; this
way, the effects of any non-specific alterations in gene
expression within individual clones on the overall
Figure 5 shRNA-mediated STAT6 silencing blocks
3H-thymidine uptake in U-1242MG and U-87MG GBM cells. Equal numbers of cells
were plated and allowed to grow in the presence of serum for 72 hours, then pulsed with
3H-thymidine prior to fixation, permeabilization and
analysis. Figure 5a: Five representative STAT6 knockdown clones of the U-1242MG cell line showed a 40-70% decrease in
3H-thymidine uptake
compared to the non-target and wild-type controls. Figure 5b: Three representative U-87MG STAT6 knockdown clones had a reduction in
3H-
thymidine uptake of 40-50% compared to controls. Error bars represent the S.E.M. and an asterisk (*) indicates statistically significant divergence
from control as determined by student t-test. Experiments were repeated a minimum of three times, and results normalized against the non-
target control. (P < 0.01)
Figure 6 Knockdown of STAT6 impairs invasion in U-1242MG and U-87MG. Equal numbers of cells were seeded into the upper
compartment of a transwell system and allowed to invade through a type IV collagen substrate for 8 hours. The invaded cells were then fixed
and counted. Figure 6a: In U-1242MG, invasion was inhibited by 25-35% in the STAT6 knockdown clones compared to the non-target and wild
type cells. Figure 6b: The effect was more dramatic in the STAT6-depleted U-87MG clones, which exhibited a decrease in invasion of 30-75%.
Error bars represent the S.E.M. and an asterisk (*) indicates statistically significant divergence from control as determined by student t-test.
Experiments were repeated a minimum of three times, and results normalized against the non-target control. (P < 0.01)
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whose expression was altered in the STAT6 knock-
down clones compared to wild type can be seen in the
additional files 1 and 2 (Additional file 1: Affymetrix
Array_U87MG_3clones vs WT.xlsx; Additional file 2:
Affymetrix Array_U1242MG_3clones vs WT and NT.xlsx)
and additional file 3, which depicts a heat map of the data
(Additional file 3: Affymetrix Array_U1242MG_U87
MG_filtered clustering.png). Tables 2 and 3 show an
abbreviated list of genes whose expression was the most
dramatically decreased in the clones of U-1242MG and U-
87MG cells, respectively. Notably, there is virtually no
overlap between the genes affected by STAT6 knockdown
in the two cell lines; it appears that STAT6 targets an
entirely different set of genes in U-1242MG and U-87MG
(Tables 2 and 3).
STAT6 gene expression correlates with survival in human
glioma patients
Based on our in vitro data (Figures 5 and 6) relating
STAT6 expression to increased GBM growth and inva-
sion, we hypothesized that increased STAT6 expression
would also correlate with a worse prognosis in glioma
patients. To test this theory, we took advantage of the
publicly available patient data in the NCI Repository for
Molecular Brain Neoplasia Data (REMBRANDT) data-
base [1]. Using microarray-based gene expression data
and associated clinical reports, we generated a Kaplan-
Meier survival curve based on differential STAT6
expression among 343 glioma patients (Figure 7A). They
included patients with GBMs (181), grade II/III astrocy-
tomas (105), grade II/III oligodendrogliomas (50), and
mixed tumors (7). Up-and down-regulation were defined
as a two-fold increase or decrease in STAT6 expression,
respectively, compared to the mean expression level
within the given data set. Based on these criteria,
STAT6 was up-regulated in ten patients, down-regu-
lated in 72 and expressed at an intermediate level in the
remaining 261 patients.
The graph shows a trend toward increased survival
times for patients with decreased STAT6 expression, as
well as a worse prognosis in cases of STAT6 up-regula-
tion (Figure 7A). However, statistical significance was
only reached when comparing survival in these two
extreme patient populations (p = 0.046 between patients
with STAT6 up- versus down-regulation), although
other comparisons would likely gain statistical signifi-
cance if the sample size were increased. Figures 7B and
7C show the same analysis performed on GBM patients
and Grade II/III astrocytoma patients, respectively. Sta-
tistical significance is not reached in these patient popu-
lations, possibly due to insufficient sample size. There is
however a trend correlating longer survival times with
lower STAT6 expression in both patient subsets.
Table 2 Genes with reduced expression levels following STAT6 knockdown in U-1242MG cells
U-1242MG
Gene Fold reduction in STAT6 clones
ATP-binding cassette, sub-family D (ALD), member 3 1.58
Vav 2 oncogene 1.59
DKFZP566K1924 protein 1.6
Endothelial differentiation, spingolipid G-protein-coupled receptor, 3 1.63
Nudix (nucleoside diphosphate linked moiety X)-type motif 1 1.67
Adipose differentiation-related protein 1.71
Laminin, gamma 2 1.93
GATA binding protein 2 1.93
Plasminogen activator, urokinase 1.98
MAD, mothers against decapentaplegic homolog 6 (Drosophila) 2.17
Interferon-induced protein 44 2.35
2’,5’-oligoadenylate synthetase 1, 40/46kDa 2.38
Heparan sulfate 6-O-sulfotransferase 1 2.41
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 2.43
KIAA1026 protein 2.59
Interferon-induced protein with tetratricopeptide repeats 4 2.6
Interleukin 18 (interferon-gamma-inducing factor) 2.93
Solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xaq), member 1 3.65
Stratifin 4.75
Viperin 4.76
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STAT proteins were originally identified as signaling
molecules involved in interferon-dependent cellular
responses [45,46]. They were soon recognized as
important mediators of cytokine production [47-50],
particularly as it pertains to development and the
immune response [9].
More recently, it has been demonstrated that STATs 3
and 5 are found in a significant percentage of human
malignancies, where they contribute to growth, survival,
Table 3 Genes with reduced expression levels following STAT6 knockdown in U-87MG cells
U-87MG
Gene Fold reduction in STAT6
clones
Matrix metalloproteinase 1 (interstitial collagenase) 2.68
Forming-like 2 2.68
Transmembrane gamma-carboxyglutamic acid protein4 2.69
Interleukin 1 family, member 8 (eta) 2.77
Gamma-aminobutyric acid (GABA) A receptor, beta 1 2.8
Rho guanine nucleotide exchange factor (GEF) 3 2.92
Protocadherin 17 2.97
Aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid
dehydrogenase
2.99
Purinergic receptor P2Y, G-protein coupled, 8 3
Major histocompatibility complex, class II, DQ alpha 1 3.09
Thymus high mobility group box protein TOX 3.14
Melanoma antigen, family E, 1, cancer/testis specific 3.17
SRY (sex determining region Y)-box 7 3.22
Lung type-I cell membrane-associated glycoprotein (PDPN/podoplanin) 3.4
Interleukin 1 receptor antagonist 3.46
Hemicentin 3.54
Aquaporin 9 3.76
Ras-related GFP binding D 3.92
Neuromedin U 4.76
Guinolinate phosphoribosyltransferase (nicotinate-nucleotide pyrophosphorylase (carboxylating)) 4.97
CD24 antigen (small cell lung carcinoma cluster 4 antigen) 5.1
Putative lymphocyte G0/G1 switch gene 5.72
Chemokine (C-X-C motif) ligand 5 5.77
Figure 7 STAT6 expression correlates with survival in human glioma patients. The Rembrandt database was used to perform a Kaplan-
Meier survival analysis of glioma patients with differential STAT6 expression. Up- and down-regulation were defined as a two-fold or greater
deviation from intermediate expression. Figure 7a: Among all glioma patients (n= 343) there was a significant difference in survival (p < 0.05)
between patients with increased vs. decreased STAT6 gene expression. Figure 7b: In the subset of patients with Grade IV tumors/GBM (n= 181),
there was a clear trend towards a similar correlation between STAT6 expression and survival; however statistical significance was not reached.
Figure 7c: In patients with Grade II/III astrocytoma (n= 105), a similar trend was observed.
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other hand renders malignant cells more susceptible to
apoptotic stimuli [57,58]. The remaining STAT family
members, namely STATs 2, 4, and 6, are still regarded
as having limited importance in cancer biology [9].
In this report, we have shown robust STAT6 protein
expression in two GBM cell lines, and further demon-
strated that STAT6 expression in these cells positively
correlated with their rate of proliferation, as well as
their invasive capacity. These findings are in agreement
with reports by others, which suggest that STAT6 is
involved in regulating the proliferation of hematopoietic
cells [34,59], fibroblasts [60] and vascular smooth mus-
cle cells [61], and that it is involved in facilitating metas-
tasis of colon cancer cells [28] as well as migration of
prostate cancer cells [62]. Suggested mechanisms
through which STAT6 enhances cell proliferation
include up-regulation of Cdk6, which facilitates cell
cycle progression, and Myc, which up-regulates addi-
tional components of the cell cycle [58]. The exact
mechanism by which STAT6 regulates proliferation and
invasion in GBM remains to be explored; however, our
microarray analysis did identify several potential STAT6
target genes which promote these behaviors in other
malignancies. For instance, the expression of matrix
metalloproteinase 1 (MMP-1) and urokinase plasmino-
gen activator (uPa) is reduced in the STAT6 knockdown
clones of U-87MG and U-1242MG cells, respectively
(Tables 2 and 3). Both MMP-1 and uPA have demon-
strated roles in facilitating invasion and metastasis of
cancer cells, presumably via degradation of the base-
ment membrane surrounding the tumor [63-66]. Lung
type I cell membrane-associated glycoprotein, also
known as podoplanin, has been implicated in promoting
invasion of astrocytomas [67]; its expression also
declines following STAT6 knockdown in U-87MG
(Table 3).
We validated the relevance of our in vitro findings by
assessing STAT6 expression in human patient astrocy-
toma specimens of different malignancy. STAT6 was
detected by IHC in the majority of human astrocytoma
specimens ranging from Grade I (pilocytic astrocytoma)
to Grade IV (GBM), but notably not in any normal
brain sections. In the patient tumors, STAT6 was loca-
lized almost exclusively in the nucleus, which suggests
that it existed in a phosphorylated (active) state- quite
unlike STAT5, which others have shown to be located
primarily in the cytoplasm [19]. The implications of this
latest finding have yet to be explored in detail.
The lack of correlation between STAT6 expression
and tumor grade suggests that STAT6 is involved early
in tumor development but is not dispensable later on as
the tumor progresses. It is possible that STAT6 per-
forms similar functions in low- and high-grade tumors;
promotion of cell proliferation for example would be
beneficial to tumors in any stage of development. On
the other hand, the apparent contribution of STAT6 to
the invasive capabilities of GBM cells contradicts such a
model, since invasion is exclusively a hallmark of high-
grade tumors. A likely scenario is that additional pro-
invasive factors must be present in order for STAT6 tar-
get genes to perform this function. It is also conceivable
that STAT6 induces expression of a different subset of
transcriptional targets based on the availability of tran-
scriptional co-factors, which likely varies between low-
and high-grade gliomas. In fact, our microarray analysis
demonstrated that STAT6 appears to have non-identical
target genes in two different GBM cell lines, suggesting
that even among Grade IV/GBM tumors, its primary
downstream effectors may differ considerably. These
results highlight the already well-documented heteroge-
neity of GBMs, and underscore the importance of
multi-target therapeutic approaches.
Lastly, we showed the clinical and potentially prognos-
tic significance of STAT6 up- and down-regulation in
glioma patients by demonstrating that STAT6 expres-
sion inversely correlates with overall survival. In a
Kaplan-Meier survival analysis of 343 glioma patient
datasets obtained from Rembrandt [1], lower STAT6
expression levels were indicative of a more favorable
prognosis compared to patients with intermediate or
high STAT6 expression. When the same analysis was
performed on data for GBM patients and Grade II/III
astrocytoma patients separately, a non-significant trend
showed a similar correlation between increased STAT6
expression and shorter survival times, suggesting that
the initial findings were not biased by differential
expression in high- versus low-grade tumors. These
findings are in perfect agreement with our earlier obser-
vations that STAT6 contributes to a more malignant
phenotype by promoting GBM cell proliferation and
invasion.
The results described here support other works advo-
cating an increasingly complex regulatory role for
STAT6 in the context of cancer. For example, reports in
the literature describe anti-apoptotic effects of STAT6
in primary B cells [68], Hodgkin lymphoma cells [58]
and colon cancer cells [35]. Others have demonstrated
the contribution of STAT6 to the suppression of an
effective anti-tumor immune response in STAT6
-/-
mice [69-74]. The combination of our findings and pub-
lished reports by other groups thus suggests multiple
functions for STAT6 in the promotion and/or mainte-
nance of tumors, including enhancement of prolifera-
tion, invasion, survival and immune evasion.
Importantly, in our study the effects of STAT6 expres-
sion on the behavior of tumor cells appear to depend
on its expression within the tumor cells themselves,
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immunological responses in STAT6
-/- animals to
STAT6 depletion in cells comprising the tumor micro-
environment [69-74]. This suggests the possibility of
synergistic benefits in response to global- rather than
tumor specific- inhibition of STAT6 in vivo.
Immuno-therapeutic approaches to GBM treatment
are generally seen as promising but thus far have been
only moderately effective [3,75,76]. The limited success
of GBM cancer vaccine trials- and cancer vaccine trials
in general- can be at least in part attributed to the fact
that many tumors, including GBM, can actively sup-
press an effective vaccine-induced immune response by
releasing specific cytokines into the tumor microenvir-
onment, thereby preventing the appropriate activation,
differentiation and/or tumor infiltration of CD8
+ T
cells [3,69]. Others have shown that STAT6 is a criti-
cal inhibitory regulator of CD8
+ T cell activation and
appropriate tissue infiltration in vivo [70,73]. Accord-
ingly, STAT6 knock-out mice (STAT6
-/- mice) have
markedly enhanced anti-tumor immunity, as demon-
strated by a reduced incidence of spontaneous primary
tumors, significantly slower growth of xenografts, a
drastically reduced incidence of metastases, and a very
low recurrence rate of surgically excised aggressive pri-
mary tumors when compared with STAT6
+/+ mice
[71-76]. Importantly, the relative resistance of the
STAT6
-/- mice to xenograft tumors suggests that the
enhanced anti-tumor immunity observed in these ani-
mals is a not a consequence of STAT6 depletion in the
tumor cells, but rather results from its loss within the
host tumor microenvironment. These findings, com-
bined with our data demonstrating the contribution of
STAT6 to the malignancy of tumor cells via promotion
of proliferation and invasion, raise the interesting possi-
bility that STAT6 may perform tumor-supportive roles
in both the tumor itself and in the surrounding stromal
compartment. This would suggest that the potential
benefits of STAT6 inhibition could be two-fold:
enhanced anti-tumor immunity combined with growth
inhibition and decreased invasive potential of the tumor
cells. Given that GBM recurrence after surgical resec-
tion is virtually 100%, a combinatorial treatment target-
ing tumor cells while also stimulating host immunity
has potential to result in improved treatment outcomes.
Conclusions
In conclusion, based on the findings in this paper and
reports in the literature, it appears that targeting STAT6
could be a promising new approach to GBM treatment,
which would potentially accomplish dual goals: it would
act on the tumor directly to slow its growth and inhibit
invasion into surrounding tissues, while simultaneously
enhancing the patient’s own immune response against
the tumor. Given that GBM is a particularly aggressive
malignancy that has been exceptionally resistant to vir-
tually all attempts at treatment, a new approach target-
ing the tumor in multiple ways may turn out to be
more effective than currently available therapies.
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